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1. INTRODUCTION {#gcc22753-sec-0001}
===============

Gastrointestinal stromal tumors (GIST) not harboring mutations in KIT or platelet‐derived growth factor receptor alpha (PDGFRA) receptors (\~10%‐15% of adult cases) are often referred to as KIT/PDGFRA wild‐type (WT) GIST.[1](#gcc22753-bib-0001){ref-type="ref"} Between 20% and 40% of KIT/PDGFRA WT GIST show loss of function of the succinate dehydrogenase complex (SDH), designated as *SDH‐deficient* GIST, recognized by the loss of subunit B (SDHB) protein expression.[2](#gcc22753-bib-0002){ref-type="ref"}, [3](#gcc22753-bib-0003){ref-type="ref"}, [4](#gcc22753-bib-0004){ref-type="ref"} Moreover, another subgroup (\~15% of KIT/PDGFRA WT GIST) harbours mutations in BRAF/RAS or NF1 and are referred to as RAS‐pathway (RAS‐P) mutant GIST.[5](#gcc22753-bib-0005){ref-type="ref"}, [6](#gcc22753-bib-0006){ref-type="ref"}, [7](#gcc22753-bib-0007){ref-type="ref"} The remaining cases, lacking mutations in the KIT/PDGFRA or RAS pathways, and retaining an intact SDH complex, are usually referred to as KIT/PDGFRA/SDH/RAS‐P WT GIST or more simply *quadruple* WT GIST, accounting approximately for 50% of KIT/PDGFRA WT GIST and 5% of all GIST.[8](#gcc22753-bib-0008){ref-type="ref"} These cases show a transcriptome profile that profoundly differs from KIT/PDGFRA‐ and SDHA‐, or possibly all SDH‐mutant GIST, indicating that *quadruple* WT GIST could represent another unique group within the family of GIST.[9](#gcc22753-bib-0009){ref-type="ref"}, [10](#gcc22753-bib-0010){ref-type="ref"}

Recently, despite the homogenous transcriptome profile, the extensive molecular characterization of *quadruple* WT GIST failed to detect any recurrent genetic event underlying the disease, conversely providing evidence of a great molecular heterogeneity, with many different and sometimes private mutational events such as fusion genes involving *ETV6‐NTRK3* or *FGFR1* and mutations on *FGFR1*, *TP53*, *MAX*, and *MEN1*.[10](#gcc22753-bib-0010){ref-type="ref"}, [11](#gcc22753-bib-0011){ref-type="ref"}, [12](#gcc22753-bib-0012){ref-type="ref"}, [13](#gcc22753-bib-0013){ref-type="ref"} However, whether these alterations were *driver* or secondary events is still to be proven, even if the heterogeneity of the mutated genes and the lack of any recurrent genetic feature supports the view that the underlying shared pathway of *quadruple* WT GIST is still to be uncovered. In this study, a deep molecular analysis was performed to further investigate the biological background of this very rare subgroup of disease that extensively differs from other GIST.

2. MATERIALS AND METHODS {#gcc22753-sec-0002}
========================

2.1. Patients and tumor samples {#gcc22753-sec-0003}
-------------------------------

Tissue samples of eight *quadruple* WT, five fresh frozen (FF), and three formalin‐fixed paraffin‐embedded (FFPE), being negative for mutations in KIT, PDGFRA, SDHx, and RAS‐P genes, were centralized at "Giorgio Prodi" Cancer Research Center (CIRC), University of Bologna, within a multicentric collaborative project. Patients and tumor characteristics are listed in Table [1](#gcc22753-tbl-0001){ref-type="table"}. GIST diagnosis was based on histologic evaluation and on immunohistochemistry of CD117 and DOG1 and was centrally reviewed. In addition to Sanger sequencing performed at the time of diagnosis, the mutational status of *KIT, PDGFRA, BRAF, KRAS, SDHx*, and *NF1* was evaluated through a custom amplicon sequencing panel using Truseq Custom Amplicon low input kit (Illumina). Moreover, SDH deficiency was excluded by IHC of SDHB. Seven out of these eight *quadruple* WT cases were also analyzed through whole exome sequencing in a previously published article[10](#gcc22753-bib-0010){ref-type="ref"} and relevant alterations were reported in four cases: a truncating mutation of *CTNND2* in GIST127, a homozygous frameshift deletion of *MEN1* and *TP53* mutation in GIST320, a frameshift deletion on *MAX* combined with a germline variant on *NF1* (p.R2573L) in GIST268, an activating mutation (p.N546K) of *FGFR1* in GIST409 (Table [1](#gcc22753-tbl-0001){ref-type="table"}).

###### 

Patients and tumor characteristics

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient id    Sex   Age   Site       Size (cm)   Mitotic count   Risk classification   Lymph node metastasis   Distant metastasis   Relevant mutations[a](#gcc22753-note-0002){ref-type="fn"}   Tissue Type   FGF4 gain      FGF4 expression
  ------------- ----- ----- ---------- ----------- --------------- --------------------- ----------------------- -------------------- ----------------------------------------------------------- ------------- -------------- -----------------
  **GIST127**   F     63    Ileum      5‐10        6‐10            High                  No                      Yes                  **CTNND2** p.S996fs                                         FF            **Positive**   **High**

  **GIST133**   M     57    Duodenum   1.6         \<5             Very low              No                      No                   None                                                        FF            **Positive**   **High**

  **GIST400**   M     69    Duodenum   NA          NA              NA                    No                      No                   None                                                        FF            **Positive**   **High**

  **GIST401**   F     45    Duodenum   NA          NA              NA                    No                      No                   None                                                        FF            **Positive**   **High**

  **GIST409**   M     45    Ileum      NA          NA              NA                    No                      No                   **FGFR1** p.N546K                                           FF            Negative       Negative

  **GIST320**   M     73    Ileum      13          \<5             High                  No                      No                   **MEN1** p.L83fs\                                           FFPE          **Positive**   **High**
                                                                                                                                      **TP53** p.V216M                                                                         

  **GIST219**   M     44    Duodenum   6.5         \>5             High                  No                      Yes                  Unknown                                                     FFPE          **Positive**   **High**

  **GIST268**   M     50    Ileum      8.5         2               Intermediate          No                      No                   **NF1** p.R2573L **MAX** p.K34fs                            FFPE          Negative       Negative
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Exome sequencing performed by Pantaleo et al.[10](#gcc22753-bib-0010){ref-type="ref"}

This study was approved by the local institutional ethical committee of Azienda Ospedaliero‐Universitaria Policlinico S.Orsola‐Malpighi (number 113/2008/U/Tess).

2.2. Copy number {#gcc22753-sec-0004}
----------------

Whole chromosome gains and losses and copy number aberrations (deletions and duplications) were determined in *quadruple* WT cases using CytoScan HD or Oncoscan CNV Plus array (Thermo Fisher Scientific, Milan, IT) for FF or FFPE specimens, respectively. Copy number data were analyzed and visualized with Chas 3.1 (Thermo Fisher Scientific).

As reference control dataset we used copy number data available online from other GIST samples: GSE93077 from Schaefer et al[14](#gcc22753-bib-0014){ref-type="ref"} and GSE20709 from Astolfi et al[15](#gcc22753-bib-0015){ref-type="ref"} GSE93077 is a series of 9 KIT mutated cases for which copy number data produced using CytoScan HD Array was available. GSE20709 is a series of 21 KIT/PDGFRA and 4 SDHx mutated GIST analyzed with SNP6.0 array. Moreover, SNP6.0 array data of additional 10 KIT/PDGFRA mutated GIST were used. Global copy number alteration were analyzed with Chas 3.1 and FGF3/FGF4 locus was manually checked for putative focal alterations.

2.3. Copy number Taqman assays {#gcc22753-sec-0005}
------------------------------

Validation of FGF4 copy number state was performed on FF *quadruple* WT tumor samples, using FAM‐labeled TaqMan Copy Number Assays (Thermo Fisher Scientific) targeting *FGF4* (Hs02374436_cn) and *XXRA1* (Hs03782780_cn), respectively, located in chromosome bands 11q13.3 and 11q13.4, were used on ABI Prism 7900HT platform (Applied Biosystems, Foster City, California). TaqMan RNaseP Control Reagent (VIC‐labeled; Thermo Fisher Scientific) was used as internal reference control. Estimation of *FGF4* copy number was done using DDCt method in comparison with *XRRA1* and with a normal diploid sample (calibrator). All experiments were performed in triplicate on the 5 *quadruple* WT cases vs 10 KIT/PDGFRA mutant GIST.

2.4. RNA‐sequencing (RNA‐seq) {#gcc22753-sec-0006}
-----------------------------

RNA‐seq data was analyzed on the 8 *quadruple* WT GIST, 5 SDH deficient GIST and 16 KIT/PDGFRA mutant samples. FF samples were analyzed as described in the previous publication.[10](#gcc22753-bib-0010){ref-type="ref"} For FFPE samples, RNA was extracted using RecoverAll Total Nucleic Acid Isolation Kit (Thermo Fisher Scientific) and cDNA libraries were synthesized from 100 ng total RNA with TruSeq RNA Exome (Illumina) according to the manufacturer\'s recommendations. Then, libraries were pooled and hybridized to probes specific for the enrichment of coding regions. Libraries were quality‐checked and sized with Bioanalyzer 2100 (Agilent Technologies), and then quantified using a fluorimetric assay (QuantIT Picogreen assay, Thermo Fisher Scientific). Paired‐end libraries were amplified and ligated to the flowcell by bridge PCR, and sequenced at 2 × 80 bp on NextSeq500 instrument (Illumina), producing an average of 50 × 10^6^ reads per sample. After FASTQ generation and trimming of low quality bases and sequencing adapters, gene expression was quantified using the tool Kallisto (https://pachterlab.github.io/kallisto/) adopting the Transcript per Million (TPM) normalization.

2.5. qRT‐PCR {#gcc22753-sec-0007}
------------

*FGF4* qRT‐PCR was performed on cDNA synthesized from FF tumor samples (5 *quadruple* WT, 5 SDH deficient, and 18 KIT/PDGFRA mutant GIST). cDNA was obtained with First Strand cDNA synthesis kit (Roche) and *FGF4* expression level was evaluated in using quantitative‐PCR on Light Cycler 480 instrument (Roche). Fold change was evaluated using DDCt method, using *GAPDH* as housekeeping gene. Primer used were: FGF4_Fw 5′‐ CCAGCCGGTTCTTCGTG‐3′; FGF4_Rev 5′‐ ATCGGTGAAGAAGGGCGAG‐3′; GAPDH_Fw 5′‐CGGGAAGCTTGTCATCAAT‐3′ and GAPDH_Rev 5′‐ GACTCCACGACGTACTCAGC‐3′.

2.6. Western blot {#gcc22753-sec-0008}
-----------------

Frozen tumor samples were homogenized in RIPA buffer containing phosphatase and protease inhibitors (Halt Protease and Phosphatase Inhibitor Cocktail, Thermo Fisher Scientific) and immunoblotted. The following primary antibodies were used: FGFR1 (\#9740, Cell Signaling, Leiden, the Netherlands), FGFR2 (\#11835, Cell Signaling), FGF4 (PA5‐52804, Thermo Fisher Scientific), phospho‐AKT (\#9271, Cell Signaling), Phospho‐c‐KIT (\#3391, Cell Signaling) and β‐Actin (A1978, Sigma‐Aldrich, Milan, Italy).

3. RESULTS {#gcc22753-sec-0009}
==========

3.1. FGF3/FGF4 locus is recurrently duplicated in quadruple WT GIST {#gcc22753-sec-0010}
-------------------------------------------------------------------

High throughput copy number analysis was performed in eight *quadruple* WT GIST, highlighting the presence of a recurrent focal gain of one copy in chromosome 11q13.3 cytoband in six samples. The cryptic copy number gain detected overlapped the FGF3/FGF4 locus, and was present either in tumors with a normal disomic chromosome 11 (Sample GIST400, 401, 133, and 219) and in two other cases (GIST127 and 320), that showed complete loss of the q‐arm of chromosome 11 (Figure [1](#gcc22753-fig-0001){ref-type="fig"}A). In addition GIST127 showed a complex copy number state in the region spanning 11q with the presence of the intrachromosomal rearrangements *MARK2‐PPFIA1* and *PLA2G16‐ATL3*, involving genes located in close proximity of the 11q13.3 copy number gain (Figure [1](#gcc22753-fig-0001){ref-type="fig"}B). Conversely, the two cases without 11q13.3 focal gain were known to carry putative pathogenetic alterations (Table [1](#gcc22753-tbl-0001){ref-type="table"}), since GIST268 harboured a germline rare variant on *NF1* and a somatic frameshift deletion on *MAX* and GIST409 carried an activating mutation (p.N546K) of *FGFR1*.[10](#gcc22753-bib-0010){ref-type="ref"}

![Identification of a recurrent focal gain of FGF3/FGF4 locus in quadruple WT GIST. A, Focal gain of chr11q13.3 identified in six cases (four FF light cyan background, two FFPE light yellow background) of quadruple WT GIST through high resolution copy number arrays. At the bottom of the image is showed the position of *FGF4* in the chr11 long arm while at the top a magnification on the FGF4 region, blue boxes indicate region of copy number gain. B, Circo plot of GIST127 chromosome 11 long arm in which are showed the experimentally‐validated rearrangements involving *MARK2‐PPFIA1* (in purple) and *PLA2G16‐ATL3* (green) that support the complexity of copy number alterations. C, Validation of FGF4 copy number gain through qPCR using Taqman assays. Four FF *quadruple* WT GIST (in light cyan) carried the gain of FGF4 (with an estimated copy number = 3), while one *quadruple* WT and 10 KIT/PDGFRA mutant cases were normal diploid (CN = 2; *P*‐value \<.01). FGF4 relative copy number was evaluated in comparison with one normal diploid sample (calibrator) and *XRRA1* (located on the adjacent cytoband of *FGF4*, chr11q13.4). *P*‐value was calculated with Mann‐Whitney test \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](GCC-58-636-g001){#gcc22753-fig-0001}

Quantitative PCR on the FGF4 region was employed to validate the copy number gain in FF *quadruple* WT, confirming the presence of the focal duplication of FGF4 in the four previously identified cases (GIST127, GIST133, GIST400, GIST401) while, as expected, GIST409 did not show the FGF4 copy number gain (Figure [1](#gcc22753-fig-0001){ref-type="fig"}C).

These findings reveal the presence of a recurrent duplication of the 11q13.3 region, encompassing*FGF3/FGF4*, in one of the two alleles at chr11 in *quadruple* WT GIST. To further assess whether 11q13.3 gain was present also in other GIST molecular subgroups, we analyzed previously produced data of 44 KIT/PDGFRA/SDHx mutant GIST (9 CytoScan HD[14](#gcc22753-bib-0014){ref-type="ref"} and 35 SNP6.0[15](#gcc22753-bib-0015){ref-type="ref"} arrays). Among these, four cases showed alterations involving 11q (two cases with trisomy of chromosome 11 and two cases with loss of the entire q‐arm), however no focal alteration involving the FGF3/FGF4 locus was detected. GIST133, a *quadruple* WT GIST, was found positive for FGF3/FGF4 gain using both CytoScan HD and SNP6.0 arrays, confirming the sensibility of both array types to detect the cryptic gain (data not shown).

3.2. FGF4 is highly expressed in quadruple WT GIST carrying FGF3/FGF4 duplication {#gcc22753-sec-0011}
---------------------------------------------------------------------------------

To understand the pathogenic effect of FGF3/FGF4 focal copy number gain, we analyzed the expression profile of 8 *quadruple* WT GIST in comparison with 5 SDH deficient and 16 KIT/PDGFRA mutant GIST. While *FGF3* was generally lowly expressed and not significantly altered among GIST subgroups, *FGF4* was found highly expressed only in *quadruple* WT samples carrying *FGF4* gain (qWT 11q13.3+), with an average expression of 163 TPM. Interestingly, the two quadruple WT cases not expressing *FGF4* were those without 11q13.3 gain (GIST268 and GIST409), supporting the correlation between the gain and the overexpression of *FGF4* (Figure [2](#gcc22753-fig-0002){ref-type="fig"}A). Conversely, *FGF4* was almost not expressed in KIT/PDGFRA mutant cases (average TPM = 0.96; *P*‐value = .0005) and significantly lowly expressed in SDH mutant cases (average TPM = 19; *P*‐value = .0043) with respect to qWT11q13.3+ (Figure [2](#gcc22753-fig-0002){ref-type="fig"}A). Through qRT‐PCR, *FGF4* was confirmed as poorly expressed in an additional cohort of 23 KIT/PDGFRA/SDH mutant GIST in comparison with qWT 11q13.3+, further supporting that the overexpression of *FGF4* is exclusive for *quadruple* WT cases with the focal duplication of the growth factor (Figure [2](#gcc22753-fig-0002){ref-type="fig"}B).

![Expression of *FGF4* and FGF receptors in *quadruple* WT with respect to KIT/PDGFRA/SDH mutant GIST. A, Log10 TPM counting, calculated from RNA‐sequencing data of 8 *quadruple* WT in comparison with 5 SDH deficient and 16 KIT/PDGFRA mutant GIST. *FGF4* (left panel) was significantly overexpressed in *quadruple* WT GIST carrying 11q13.3 gain. *P*‐value was calculated with Mann‐Whitney test (\*\*\<.01; \*\*\*\<.001). On the right panel, FGF receptors mRNA expression level is shown: while *FGFR3* and *FGFR4* are lowly expressed, *FGFR1* and *FGFR2* are highly expressed and present in *quadruple* WT GIST at a levels comparable to KIT/PDGFRA/SDH mutant cases. B, FGF4 mRNA relative expression evaluated through qRT‐PCR on FF tumor samples (5 *quadruple* WT, 5 SDH deficient, and 18 KIT/PDGFRA mutant GIST). C, Western blot evaluation of protein expression level of FGF4, FGFR1 and FGFR2 in *quadruple* WT GIST. Cell lines lysates were used as positive controls: untreated GIST48 and GIST48 supplemented with 100 μg/mL of recombinant FGF4 protein (for FGFR1 and FGF4 expression) and untreated SNU‐16 (for FGFR2 expression). β‐Actin was used as loading control. D, Evaluation of KIT and AKT phosphorylation level in GIST tumors. β‐Actin was used as loading control \[Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)\]](GCC-58-636-g002){#gcc22753-fig-0002}

Expression of FGF4 receptors was evaluated at the mRNA level, finding two out of four FGF receptors (FGFR1 and 2) expressed in all GIST subgroups, with FGFR1 being the most expressed (FGFR1 average‐TPM = 361 vs FGFR2 average‐TPM = 47) (Figure [2](#gcc22753-fig-0002){ref-type="fig"}A). At the protein level FGFR1 was confirmed as the predominant FGF receptor commonly expressed in all GIST, while the ligand FGF4 was detected only in the *quadruple* WT subgroup (Figure [2](#gcc22753-fig-0002){ref-type="fig"}C). GIST409, similarly to KIT‐mutant GIST, did not express FGF4 protein (Figure [2](#gcc22753-fig-0002){ref-type="fig"}C).

We then investigated whether FGF4 could activate its downstream signaling. Interestingly, while KIT phosphorylation was not detected in *quadruple* WT GIST, phosphorylation of AKT was detected also in *quadruple* WT GIST, suggesting the presence of a FGF4/FGFR1 autocrine loop that activates downstream signaling in this subgroup (Figure [2](#gcc22753-fig-0002){ref-type="fig"}D).

Together these findings suggest that the recurrent 11q13.3 duplication detected in *quadruple* WT is the pathogenic *driver* event, provoking the overexpression of *FGF4* and the activation of FGFR1 downstream signaling.

4. DISCUSSION {#gcc22753-sec-0012}
=============

In the present study we discovered the presence of a recurrent focal copy number gain encompassing the FGF3/FGF4 locus specifically in *quadruple* WT GIST, which was associated with a high expression of *FGF4*. Fibroblast growth factor 4 has a key role in maintaining the self‐renewal potential of normal stem cells[16](#gcc22753-bib-0016){ref-type="ref"} and it is usually not expressed in human adult tissues (with the exception of testis).[17](#gcc22753-bib-0017){ref-type="ref"} It was firstly identified as an oncogene in gastric cancer and Kaposi\'s sarcoma[18](#gcc22753-bib-0018){ref-type="ref"}, [19](#gcc22753-bib-0019){ref-type="ref"} and it has been found overexpressed in several malignancies (including germ cell tumors, ovarian cancer, hepatocellular carcinoma, and lung adenocarcinoma), generally associated with aggressiveness and poorer prognosis.[17](#gcc22753-bib-0017){ref-type="ref"}, [20](#gcc22753-bib-0020){ref-type="ref"}, [21](#gcc22753-bib-0021){ref-type="ref"}, [22](#gcc22753-bib-0022){ref-type="ref"} In our cases, the cryptic duplication of FGF3/FGF4 was predominantly found in tumors with a normal disomic chromosome 11, however, it was detected also in cases showing the complete loss of one of the two copies of the q‐arm of the chromosome. Both genes are located in the 11q13 cytoband, and together with *FGF19*, *EMS1*, and *CCND1* are frequently amplified in solid cancers including breast cancer, squamous cell carcinoma, esophageal cancer, bladder cancer, and hepatocellular carcinoma.[23](#gcc22753-bib-0023){ref-type="ref"}, [24](#gcc22753-bib-0024){ref-type="ref"}, [25](#gcc22753-bib-0025){ref-type="ref"}, [26](#gcc22753-bib-0026){ref-type="ref"}, [27](#gcc22753-bib-0027){ref-type="ref"} Interestingly, through in vitro and in vivo studies in hepatocellular carcinoma, FGF3/FGF4 focal amplification was demonstrated to be related to *FGF3* and *FGF4* overexpression and to an increased sensitivity to sorafenib.[21](#gcc22753-bib-0021){ref-type="ref"}

Noticeably, while *FGF4* was absent or slightly expressed in KIT/PDGFRA/SDH‐mutated GIST, it was found highly expressed in *quadruple* WT GIST, supporting a causal role of the gain in the transcriptional activation of the gene. On the other hand, no significant upregulation of *FGF3* was detected, indicating that this gene may not be the biologically‐relevant pathogenic event. The mechanism for which the duplication found in *quadruple* WT GIST leads to the re‐activation of *FGF4* transcription is not clear. However, it could be hypothesized that this alteration may cause conformational or epigenetic changes able to disrupt the silencing of the gene, possibly through an escape from the epigenetic repression of *FGF4* transcription.[28](#gcc22753-bib-0028){ref-type="ref"}

The novelty and interest of these findings are that, for the first time, a recurrent event shared by the majority of *quadruple* WT GIST was identified in this subgroup of disease that until now was characterized only by private and heterogeneous molecular events. Therefore, this opens a new molecular path of study in this very rare disease. Predominantly, *quadruple* WT GIST positive for *FGF4* duplication were shown to be negative for any other relevant alterations, with the exception of one case mutated in *MEN1* and one carrying *CTNND2* inactivation. On the other side, the two *quadruple* WT cases negative for *FGF4* expression showed other relevant alterations: *MAX* inactivation and a *NF1* germline variant in one case and a *FGFR1* p.N546K activating mutation in the other.[10](#gcc22753-bib-0010){ref-type="ref"}

In previous works, *quadruple* WT GIST have been shown to carry a homogeneous signature profile,[9](#gcc22753-bib-0009){ref-type="ref"}, [10](#gcc22753-bib-0010){ref-type="ref"} however, no recurrent genetic alteration has been detected so far.[13](#gcc22753-bib-0013){ref-type="ref"} Interestingly, among the alterations identified, three different events affecting FGFR1 were detected: *FGFR1* p.N546K mutation[10](#gcc22753-bib-0010){ref-type="ref"}, [11](#gcc22753-bib-0011){ref-type="ref"} and *FGFR1‐HOOK3* and *FGFR1‐TACC1* fusion genes.[11](#gcc22753-bib-0011){ref-type="ref"} These events are predicted to constitutively activate FGFR1 and the downstream signaling pathways. A mechanism of an autocrine FGF2/FGFR1 activation loop controlling AKT signaling has been identified in many cancer histotypes, including non small cell lung cancer and malignant pleural mesothelioma, in which it may be predictive of drug response.[29](#gcc22753-bib-0029){ref-type="ref"}, [30](#gcc22753-bib-0030){ref-type="ref"} Intriguingly, FGF4 is reported to be a ligand of all four FGF receptors, including FGFR1, which we have demonstrated to be highly expressed in GIST including *quadruple* WT cases. It could be hypothesized that in these FGF4‐positive GIST, an autocrine loop between FGF4 and FGFR1 is present, supporting tumor growth. Indeed, we demonstrated that signaling through AKT is active in *quadruple* WT GIST, suggesting that, in the absence of KIT phosphorylation, activation of FGFR1 through the autocrine loop could stimulate downstream signaling. Interestingly, the case harboring *FGFR1* p.N546K mutation did not show expression of FGF4, suggesting that only one alteration in the same pathway is necessary and sufficient to activate downstream signaling. Additional studies further investigating the role of *FGF4* overexpression in tumor growth and in FGFR signaling activation will be necessary to confirm these hypotheses.

Altogether, these findings support a potential involvement in disease onset of the FGFR pathway deregulation shared by all *quadruple* WT GIST suggesting a possible role for FGRF inhibitors. Evaluation of nonselective FGFR inhibitors (eg, regorafenib, sorafenib, ponatinib, pazopanib, dovitinib) was well known, however no information on the activity of these treatments are available specifically in KIT/PDGFRA WT GIST.[31](#gcc22753-bib-0031){ref-type="ref"} Therefore, selective FGFR inhibitors (eg, AZD4547, BGJ398) could be considered for the treatment of this subgroup of GIST. Recently, a cross‐talk between KIT and FGFR playing an important role in imatinib resistance was reported and a clinical trial with BGJ398 in combination with imatinib was conducted in advanced GIST.[32](#gcc22753-bib-0032){ref-type="ref"}, [33](#gcc22753-bib-0033){ref-type="ref"} In our series, no patient had received treatment with FGFR inhibitors.

Due to the small number of cases and the clinical heterogeneity, we cannot postulate any definitive consideration regarding the prognostic or predictive significance or clinical association of FGF3/FGF4 duplication from our series. In fact, in localized cases risk of recurrence ranged from very low to high, while the two metastatic cases did not receive regorafenib. There was no gender or age predominance in patients. The only interesting clinical data were that all *quadruple* WT cases developed GIST in the small bowel and did not present lymph nodes metastases, as these occur mostly in SDH‐deficient GIST.

In conclusion, for the first time a recurrent event shared by *quadruple* WT GIST is reported in this study, even if these findings should be tested and confirmed in larger series. Gain of *FGF4*, together with *FGFR1* mutations, represents the most frequent molecular alteration identified in this subgroup so far, suggesting that these specific driver events could aid the diagnostic process of KIT/PDGFRA/SDH/RAS‐P WT GIST, that are currently still diagnosed only by exclusion, and, most important, that FGFR pathway activation could provide a rationale for targeted therapeutic approaches.
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